Liver and biliary tract cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 91
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• MAPK 0
• HER2 28
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• STING 0
• EGFR 8
• CTLA-4 19
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• CDK4/6 0
• IL-15 2

24 of 54+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Germany· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Italy· EU contribution €193,643· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Denmark· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spain· EU contribution €2,499,745· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 39 running projects, newest first. Listed amounts together: €133.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Updated 15 Sept 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Trial of SHR1258 in Patients With Biliary Tract Cancer

  NCT04571710· Jiangsu HengRui Medicine Co., Ltd.· Updated 24 Jul 2025

  “The sponsor's R\&D strategy is adjusted.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Jazz Pharmaceuticals· Source

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Source

• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· AstraZeneca· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

• Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  NCT05523947· Yuhan Corporation· Source

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Source

• A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER

  NCT07515950· MedSIR· Source

• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

  NCT04430738· Seagen, a wholly owned subsidiary of Pfizer· Source

• A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

  NCT04466891· Jazz Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 41
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 198
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• Artificial Intelligence in Gallbladder Carcinoma: A Review of Research Studies and Clinical Evidence.

  J Gastrointest Cancer, Nov 2026

• Artificial intelligence in hepatitis: Advances in diagnosis, treatment optimization, and prognostic prediction.

  J Int Med Res, Oct 2026

• ITO-based multi-band metasurface absorber for early detection of hepatic cancer through deep learning.

  Opt Express, Oct 2026

• Deep learning-based CNN method for fiducial marker detection in kilovoltage X-ray images for liver tumor motion monitoring.

  Med Phys, Oct 2026

• Radiomics and deep learning for immune checkpoint inhibitor outcomes: imaging-derived immune phenotyping and clinical translation across solid tumors.

  Front Immunol, Sept 2026

• Development and external validation of an interpretable deep learning model for early immune-related adverse events in hepatocellular carcinoma.

  Front Immunol, Sept 2026

• An MRI-Based Intratumoral and Peritumoral 2.5D Deep Learning Model for Predicting P53-Mutated Hepatocellular Carcinoma: A Two-Center Study.

  Technol Cancer Res Treat, Sept 2026

• Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma.

  Nat Commun, Sept 2026

• Interpretable prediction of macrotrabecular-massive HCC and recurrence-free survival by integrating MRI LI-RADS features with deep learning habitat radiomics.

  Eur Radiol Exp, Sept 2026

• A Vision Transformer- and Radiomics-based Model for Predicting Liver Metastasis-Free Survival in Patients with Rectal Cancer.

  Radiol Imaging Cancer, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.